KALARIS THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
KALARIS THERAPEUTICS, INC. (KLRS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$28.86 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-12-31 was $3.83M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-09-30 was -$7.28M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-06-30 was -$9.68M, a 279.42% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-03-31 was -$15.73M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$28.86M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$2.51M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$12.62M, a 162.21% decline from fiscal 2021.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $20.29M, a 644.31% increase from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$3.45M derived: sum of 2 quarters · filed 2025-03-07 | -$13.13M derived: sum of 3 quarters · filed 2025-03-07 | -$28.86M 10-K · filed 2025-03-07 |
| 2024-09-30 | -$7.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$16.96M derived: sum of 2 quarters · filed 2024-11-12 | -$32.69M 10-Q · filed 2024-11-12 | -$38.24M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | -$9.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$25.41M 10-Q · filed 2024-08-09 | -$30.96M derived: sum of 3 quarters · filed 2025-03-07 | -$32.83M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | -$15.73M 10-Q · filed 2024-05-13 | -$21.29M derived: sum of 2 quarters · filed 2025-03-07 | -$23.15M derived: sum of 3 quarters · filed 2025-03-07 | -$17.76M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | -$5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$7.42M derived: sum of 2 quarters · filed 2025-03-07 | -$2.03M derived: sum of 3 quarters · filed 2025-03-07 | -$2.51M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.53M derived: sum of 2 quarters · filed 2024-11-12 | $3.04M 10-Q · filed 2024-11-12 | $1.31M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $5.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $4.91M 10-Q · filed 2024-08-09 | $3.17M derived: sum of 3 quarters · filed 2024-08-09 | $2.65M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$486.00K 10-Q · filed 2024-05-13 | -$2.22M derived: sum of 2 quarters · filed 2024-05-13 | -$2.74M derived: sum of 3 quarters · filed 2024-05-13 | $678.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$2.26M derived: sum of 2 quarters · filed 2024-03-15 | $1.16M derived: sum of 3 quarters · filed 2024-03-15 | -$12.62M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$521.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.90M derived: sum of 2 quarters · filed 2023-11-02 | -$10.89M 10-Q · filed 2023-11-02 | $592.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$10.37M 10-Q · filed 2023-08-03 | $1.11M derived: sum of 3 quarters · filed 2023-08-03 | $3.20M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$13.79M 10-Q · filed 2023-05-04 | -$2.31M derived: sum of 2 quarters · filed 2023-05-04 | -$219.00K derived: sum of 3 quarters · filed 2023-05-04 | $4.85M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $11.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $13.57M derived: sum of 2 quarters · filed 2023-02-15 | $18.64M derived: sum of 3 quarters · filed 2023-02-15 | $20.29M 10-K · filed 2023-02-15 |
| 2021-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.16M derived: sum of 2 quarters · filed 2022-11-03 | $8.81M 10-Q · filed 2022-11-03 | $7.24M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.72M 10-Q · filed 2022-08-04 | $5.15M derived: sum of 3 quarters · filed 2022-08-04 | $9.72M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.65M 10-Q · filed 2022-05-05 | $81.00K derived: sum of 2 quarters · filed 2022-05-05 | $4.65M derived: sum of 3 quarters · filed 2022-05-05 | $5.84M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $3.00M derived: sum of 2 quarters · filed 2022-02-10 | $4.19M derived: sum of 3 quarters · filed 2022-02-10 | $2.73M 10-K · filed 2022-02-10 |
| 2020-09-30 | $4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $5.76M derived: sum of 2 quarters · filed 2021-11-05 | $4.29M 10-Q · filed 2021-11-05 | $6.20M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$271.00K 10-Q · filed 2021-08-06 | $1.64M derived: sum of 3 quarters · filed 2021-08-06 | $2.62M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | -$1.46M 10-Q · filed 2021-05-06 | $445.00K derived: sum of 2 quarters · filed 2021-05-06 | $1.42M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $2.89M derived: sum of 2 quarters · filed 2021-02-12 | $4.94M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $979.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.03M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $2.05M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |